bioRxivCancer BiologyPreprint
A triple-negative matrix-producing breast carcinoma is arrested by tumor-targeting Salmonella typhimurium A1-R in a PDOX model
K. Hamada, J. Yamamoto, C. Hozumi, M. Zhao, T. Murata, N. Sugisawa, Y. Sun, Y. Aoki, H. Nishino, M. Bouvet, T. Tsunoda, R. M. Hoffman
Abstract
Background/AimMatrix-producing breast carcinoma (MPBC), is a rare, recalcitrant and highly aggressive. The present study aimed to determine the efficacy of tumor-targeting Salmonella typhimurium (S. typhimurium) A1-R on a triple-negative MPBC in a patient-derived orthotopic xenograft (PDOX) model. MethodsThe PDOX model was established in the left second mammary gland of a nude mouse by surgical orthotopic implantation (SOI) of the patient triple-negative MPBC PDOX models were randomized into two groups: G1, control group (n=6); G2, tumor-targeting S. typhimurium A1-R group (n=7, intravenous (i.v.) injection via tail vein, weekly, for two weeks). All mice were sacrificed on day 15. Tumor volume and body weight were measured one time per week. ResultsS. typhimurium A1-R arrested tumor growth compared to the control group (P = 0.016). ConclusionThe results of the present study suggest that S. typhimurium A1-R has future clinical potential in triple-negative MPBC patients.
- organism: mouse
- research focus: cancer & tumor microenvironment
- research focus: drug response / drug discovery
- research focus: benchmarking
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Murine models for triple-negative breast cancer with differential responsiveness to immunotherapy
Thomas J. Kalantzakos, Yufan Zhou, … Reuben S. Harris·Journal of Clinical and Translational SciencePeer-reviewed·Apr 1, 2026
- Reshaping the Landscape of Locoregional Treatments for Breast Cancer Liver Metastases: A novel, intratumoral, p21-targeted percutaneous therapy increases survival in BALB/c mice inoculated with 4T1 triple negative breast cancer cells in the liver.
Bryan Samuel Margulies, Morakot Likhitpanichkul, Debu Tripathy·PLoS ONEPeer-reviewed·Jun 5, 2025
- Survivin (BIRC5) peptide vaccine in the 4T1 murine mammary tumor model: a potential neoadjuvant T-cell immunotherapy for triple negative breast cancer.
S. R. Burkholz, C. V. Herst, … R. M. Rubsamen·bioRxiv·Jul 25, 2022
- Attenuated Salmonella typhimurium cancer therapy has direct effects on the tumor epithelium in colorectal cancer
K. M. Maslowski, M. Takahashi, … H. Ohno·bioRxiv·Aug 21, 2019
- A Novel Mouse Model that Recapitulates the Heterogeneity of Human Triple Negative Breast Cancer
Z. O. Doha, X. Wang, … R. C. Sears·bioRxiv·Oct 7, 2022
- Modeling Heterogeneity of Triple-Negative Breast Cancer Uncovers a Novel Combinatorial Treatment Overcoming Primary Drug Resistance
F. Lamballe, F. Ahmad, … F. Maina·bioRxiv·Jun 22, 2020